Telix Pharmaceuticals Limited (ASX:TLX)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Precision Medicine	621.93M	508.51M	329.21M	-		-
Precision Medicine Growth	22.30%	54.47%	-	-		-
Therapeutics	9.27M	6.23M	3.50M	-		-
Therapeutics Growth	48.94%	78.09%	-	-		-
Manufacturing Solutions	245.11M	1.82M	277.00K	-		-
Manufacturing Solutions Growth	13389.54%	555.96%	-	-		-
Inter-Segment Elimination	-72.51M	-	-	-		-
Commercial	-	-	-	106.28M		-
Product Development	-	-	-	2.53M		-
Pharmaceuticals	-	-	-	-		4.02M
Pharmaceuticals Growth	-	-	-	-		64.26%
Total	803.79M	516.55M	332.98M	108.81M		4.02M
Total Growth	55.61%	55.13%	206.01%	-		64.26%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Jan 1, 2024	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	9.83M	382.00K	863.00K	2.28M		-
China Growth	2474.35%	-55.74%	-62.13%	-		-
United States	784.91M	502.76M	324.47M	101.95M		-
United States Growth	56.12%	54.95%	218.25%	-		-
Other Countries	9.06M	13.41M	7.64M	2.70M		-
Other Countries Growth	-32.47%	75.49%	182.54%	-		-
Australia	-	-	-	101.27K		4.02M
Australia Growth	-	-	-	-		64.26%
Belgium	-	-	-	383.33K		-
United Kingdom	-	-	-	1.39M		-
Total	803.79M	516.55M	332.98M	108.81M		4.02M
Total Growth	55.61%	55.13%	206.01%	-		64.26%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 12, 2026

Data Sources Report a data error